Attar Sabah, Figueiras Francisca P, Peacock Carla, Wohlfahrt Hazel, Hüsken Birgitta C P, Andrews Susan, Lepola Pirkko, Patton Margaret, Hankard Regis, Halil Eren, Soares Fernando Pontes, Tan Lionel K, Fernandes Ricardo M, Turner Mark A
Department of Women's and Children's Health, Liverpool Women's NHS Foundation Trust, University of Liverpool, Liverpool, United Kingdom.
conect4children Stichting, Utrecht, Netherlands.
Front Med (Lausanne). 2025 Jun 9;12:1531276. doi: 10.3389/fmed.2025.1531276. eCollection 2025.
The efficiency, quality, and scalability of clinical trial support services are essential for the success of multinational clinical trials particularly trials that recruit babies, children, and young people. Through a public private partnership funded by the Innovative Medicines Initiative 2 between 2018 and 2025 involving 10 large originator pharmaceutical companies and 33 academic and third sector organizations, the conect4children (c4c) network has developed high-quality trial support services to promote consistent delivery in pediatric trials in over 220 sites across 21 countries, addressing gaps in communication, site identification, feasibility, and trial support. This paper explores the development and implementation of these services, using the Technology Readiness Levels (TRLs) and Service Readiness Levels (SRLs) frameworks to measure service progression and operational maturity. The initiative successfully streamlined targeted aspects of trial support. Over 6 years the multinational coordination of pediatric trials moved from SRL1 to SRL8 and services have been deployed in a sustainable non-profit organization. Challenges encountered include variability in site readiness for clinical trials and processes. Differences between companies in methodologies for collecting data about trial setup prevented clear understanding of the benefits of the c4c approach. Sustainability of long-term infrastructure beyond IMI2 funding will be managed by a new, independent, non-profit organization, conect4children Stichting based on scale up of services provided to industry and academia. The findings provide generalizable insights and lessons applicable to other research networks seeking to build or improve similar infrastructures.
临床试验支持服务的效率、质量和可扩展性对于跨国临床试验的成功至关重要,尤其是针对招募婴儿、儿童和青少年的试验。通过由创新药物倡议2在2018年至2025年资助的公私合作伙伴关系,该合作涉及10家大型原创制药公司以及33个学术和第三部门组织,conect4children(c4c)网络已开发出高质量的试验支持服务,以促进在21个国家/地区的220多个地点进行的儿科试验中的一致交付,解决沟通、地点识别、可行性和试验支持方面的差距。本文探讨了这些服务的开发和实施情况,使用技术就绪水平(TRL)和服务就绪水平(SRL)框架来衡量服务进展和运营成熟度。该倡议成功简化了试验支持的目标方面。在6年多的时间里,儿科试验的跨国协调从SRL1提升到了SRL8,并且服务已在一个可持续的非营利组织中部署。遇到的挑战包括临床试验地点准备情况和流程的差异。公司在收集试验设置数据的方法上存在差异,这妨碍了对c4c方法益处的清晰理解。IMI2资金以外的长期基础设施的可持续性将由一个新的独立非营利组织conect4children Stichting来管理,该组织基于向行业和学术界提供的服务规模扩大。这些发现提供了适用于其他寻求建立或改善类似基础设施的研究网络的可推广见解和经验教训。